Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response

JAMA - Journal of the American Medical Association

Volumn 313, Issue 16, 2015, Pages 1645-1656

  Viatte, Sebastien ^a   Plant, Darren ^a,b   Han, Buhm ^c,d,e,n   Fu, Bo ^a,f   Yarwood, Annie ^a   Thomson, Wendy ^a,b   Symmons, Deborah P M ^b,g   Worthington, Jane ^a,b   Young, Adam ^h,i   Hyrich, Kimme L ^g   Morgan, Ann W ^j,k   Wilson, Anthony G ^l   Isaacs, John D ^m   Raychaudhuri, Soumya ^a,c,d,e   Barton, Anne ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c HARVARD UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e LABORATORY FOR MOLECULAR MEDICINE   (United States)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h St Albans City Hospital   (United Kingdom)

ⁱ UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^j CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^k UNIVERSITY OF LEEDS   (United Kingdom)

^l UNIVERSITY COLLEGE DUBLIN   (Ireland)

^m NEWCASTLE UNIVERSITY   (United Kingdom)

ⁿ University of Ulsan College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA DRB1 ANTIGEN; TUMOR NECROSIS FACTOR INHIBITOR; VALINE; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BONE EROSION; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DISEASE PREDISPOSITION; DISEASE SEVERITY; EUROPEAN LEAGUE AGAINST RHEUMATISM RESPONSE; FEMALE; FOLLOW UP; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; JOINT RADIOGRAPHY; LARSEN SCORE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MORTALITY; MUSCULOSKELETAL DISEASE ASSESSMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGISTER; REPLICATION STUDY; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; UNITED KINGDOM; ALLELE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CAUCASIAN; EPIDEMIOLOGY; FOOT; GENETICS; HAND; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; ALLELES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOOT; GENOTYPE; GREAT BRITAIN; HAND; HAPLOTYPES; HETEROZYGOTE; HLA-DRB1 CHAINS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928731411     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.3435     Document Type: Article

References (38)

1. Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):141-153.
2. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. Arthritis Rheum. 1987;30(11):1205-1213.
3. Bukhari M, Thomson W, Naseem H, et al. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis. Arthritis Rheum. 2007;56(9):2929-2935.
4. Viatte S, Barton A. The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease. Eur Musculoskeletal Rev. 2012;7(2):102-107.
5. Ajeganova S, Andersson ML, Frostegård J, Hafström I. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset. J Rheumatol. 2013;40(12):1958-1966.
6. Farragher TM, Goodson NJ, Naseem H, et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum. 2008;58(2):359-369.
7. Criswell LA, Lum RF, Turner KN, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004;50(9):2750-2756.
8. Cui J, Stahl EA, Saevarsdottir S, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 2013;9(3):e1003394.
9. Plant D, Bowes J, Potter C, et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 2011;63(3):645-653.
10. Plant D, Wilson AG, Barton A. Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol. 2014;10(6):329-337.
11. Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012;44(3):291-296.
12. Plant D, Thomson W, Lunt M, et al. The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis. Rheumatology (Oxford). 2011;50(1):78-84.
13. Symmons DP, Silman AJ. The Norfolk Arthritis Register (NOAR). Clin Exp Rheumatol. 2003;21(5)(suppl 31):S94-S99.
14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324.
15. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh). 1977;18(4):481-491.
16. Solymossy C, Dixey J, Utley M, et al. Larsen scoring of digitized X-ray images. Rheumatology (Oxford). 1999;38(11):1127-1129.
17. Viatte S, Plant D, Lunt M, et al. Investigation of rheumatoid arthritis genetic susceptibility markers in the early rheumatoid arthritis study further replicates the TRAF1 association with radiological damage. J Rheumatol. 2013;40(2):144-156.
18. James D, Young A, Kulinskaya E, et al. Orthopaedic intervention in early rheumatoid arthritis. Rheumatology (Oxford). 2004;43(3):369-376.
19. Farragher TM, Plant D, Flynn E, et al. Association of a rheumatoid arthritis susceptibility variant at the CCL21 locus with premature mortality in inflammatory polyarthritis patients. Arthritis Care Res (Hoboken). 2010;62(5):676-682.
20. Ibrahim I, McAllister K, Plant D, et al. Investigation of an interleukin-6 receptor gene polymorphism (rs2228145) as a predictor of cardiovascular mortality in inflammatory polyarthritis. Ann Rheum Dis. 2014;73(4):787-788.
21. Statistics and Registration Service Act 2007.
22. Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45(12):1558-1565.
23. Plant D, Prajapati R, Hyrich KL, et al. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum. 2012;64(3):665-670.
24. Thomson W, Harrison B, Ollier B, et al. Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis. Arthritis Rheum. 1999;42(4):757-762.
25. Viatte S, Plant D, Bowes J, et al. Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Ann Rheum Dis. 2012;71(12):1984-1990.
26. Eyre S, Bowes J, Diogo D, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet. 2012;44(12):1336-1340.
27. Jia X, Han B, Onengut-Gumuscu S, et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One. 2013;8(6):e64683.
28. Yarwood A, Han B, Raychaudhuri S, et al. A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Ann Rheum Dis. 2015;74(1):170-176.
29. Rabe-Hesketh S, Skrondal A, Pickles A. Generalized multilevel structural equation modelling. Psychometrika. 2004;69:167-190.
30. Rabe-Hesketh S, Skrondal A, Pickles A. Maximum likelihood estimation of limited and discrete dependent variable models with nested random effects. J Econom. 2005;128:301-323.
31. Rabe-Hesketh S, Skrondal A. Classical latent variable models for medical research. Stat Methods Med Res. 2008;17(1):5-32.
32. Lee JC, Espéli M, Anderson CA, et al. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell. 2013;155(1):57-69.
33. van Gestel AM, Prevoo ML, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum. 1996;39(1):34-40.
34. Barra L, Pope JE, Payne M. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2009;36(7):1421-1428.
35. Karlson EW, Chibnik LB, Kraft P, et al. Cumulative association of 22 genetic variants with seropositive rheumatoid arthritis risk. Ann Rheum Dis. 2010;69(6):1077-1085.
36. Norton S, Sacker A, Dixey J, Done J, Williams P, Young A. Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality. Rheumatology (Oxford). 2013;52(11):2016-2024.
37. Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68(1):69-74.
38. Bruynesteyn K, van der Heijde D, Boers M, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoringmethods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum. 2002;46(4):913-920.